151 related articles for article (PubMed ID: 18485571)
1. Editorial comment on: Cizolirtine citrate, an effective treatment for symptomatic patients with urinary incontinence secondary to overactive bladder: a pilot dose-finding study.
May F; Bauer R
Eur Urol; 2009 Jul; 56(1):191. PubMed ID: 18485571
[No Abstract] [Full Text] [Related]
2. Cizolirtine citrate, an effective treatment for symptomatic patients with urinary incontinence secondary to overactive bladder: a pilot dose-finding study.
Martínez-García R; Abadías M; Arañó P; Perales L; Ruíz JL; Sust M; Conejero J;
Eur Urol; 2009 Jul; 56(1):184-90. PubMed ID: 18485575
[TBL] [Abstract][Full Text] [Related]
3. Editorial comment on: Cizolirtine citrate, an effective treatment for symptomatic patients with urinary incontinence secondary to overactive bladder: a pilot dose-finding study.
Lazzeri M
Eur Urol; 2009 Jul; 56(1):191-2. PubMed ID: 18485574
[No Abstract] [Full Text] [Related]
4. Editorial comment on: Cizolirtine citrate is safe and effective for treating urinary incontinence secondary to overactive bladder: a phase 2 proof-of-concept study.
Costantini E; Lazzeri M
Eur Urol; 2010 Jan; 57(1):152-3. PubMed ID: 19446952
[No Abstract] [Full Text] [Related]
5. Editorial comment on: Cizolirtine citrate is safe and effective to treat urinary incontinence secondary to overactive bladder: a phase 2 proof-of-concept study.
Soljanik I
Eur Urol; 2010 Jan; 57(1):153. PubMed ID: 19446950
[No Abstract] [Full Text] [Related]
6. Cizolirtine citrate is safe and effective for treating urinary incontinence secondary to overactive bladder: a phase 2 proof-of-concept study.
Zát'ura F; Vsetica J; Abadías M; Pavlík I; Schraml P; Brod'ák M; Villoria J; Sust M;
Eur Urol; 2010 Jan; 57(1):145-52. PubMed ID: 19446951
[TBL] [Abstract][Full Text] [Related]
7. Overactive bladder pharmacotherapy: what does the future hold?
Dmochowski RR
BJU Int; 2007 Jun; 99 Suppl 3():13-6. PubMed ID: 17488368
[No Abstract] [Full Text] [Related]
8. [Comment on the STAR study: Comparison of the efficacy and tolerance of solifenacin and tolterodine retard in the treatment of overactive bladder].
Goepel M
Urologe A; 2006 Jul; 45(7):847-51. PubMed ID: 16816976
[No Abstract] [Full Text] [Related]
9. Pharmacologic management of urinary incontinence, voiding dysfunction, and overactive bladder.
Saks EK; Arya LA
Obstet Gynecol Clin North Am; 2009 Sep; 36(3):493-507. PubMed ID: 19932412
[TBL] [Abstract][Full Text] [Related]
10. Editorial comment on: Urinary incontinence at orgasm: relation to detrusor overactivity and treatment efficacy.
Kuo HC
Eur Urol; 2008 Oct; 54(4):915-6. PubMed ID: 18036725
[No Abstract] [Full Text] [Related]
11. Editorial comment on: Urinary incontinence at orgasm: relation to detrusor overactivity and treatment efficacy.
Roumeguère T
Eur Urol; 2008 Oct; 54(4):916-7. PubMed ID: 18036722
[No Abstract] [Full Text] [Related]
12. Overactive bladder syndrome in older people.
Wagg AS; Cardozo L; Chapple C; De Ridder D; Kelleher C; Kirby M; Milsom I; Vierhout M
BJU Int; 2007 Mar; 99(3):502-9. PubMed ID: 17407511
[TBL] [Abstract][Full Text] [Related]
13. [The recommendations of the Polish Gynecologic Society regarding the use of darifenacin, selective muscarinic antagonists in the treatment of overactive bladder].
Ginekol Pol; 2007 Oct; 78(10):815-20. PubMed ID: 18200976
[No Abstract] [Full Text] [Related]
14. Oxybutynin transdermal system improves the quality of life in adults with overactive bladder: a multicentre, community-based, randomized study.
Sand P; Zinner N; Newman D; Lucente V; Dmochowski R; Kelleher C; Dahl NV
BJU Int; 2007 Apr; 99(4):836-44. PubMed ID: 17187655
[TBL] [Abstract][Full Text] [Related]
15. Mirabegron as Add-On Treatment to Solifenacin in Patients with Incontinent Overactive Bladder and an Inadequate Response to Solifenacin Monotherapy: Responder Analyses and Patient-Reported Outcomes from the BESIDE Study [corrected].
MacDiarmid S; Al-Shukri S; Barkin J; Fianu-Jonasson A; Grise P; Herschorn S; Saleem T; Huang M; Siddiqui E; Stölzel M; Hemsted C; Nazir J; Hakimi Z; Drake MJ;
J Urol; 2016 Sep; 196(3):809-18. PubMed ID: 27063854
[TBL] [Abstract][Full Text] [Related]
16. Do gender, age or lifestyle factors affect responses to antimuscarinic treatment in overactive bladder patients?
Schneider T; Marschall-Kehrel D; Hanisch JU; Michel MC
Int J Clin Pract; 2010 Aug; 64(9):1287-93. PubMed ID: 20500534
[TBL] [Abstract][Full Text] [Related]
17. Achieving continence with antimuscarinic therapy for overactive bladder: effects of baseline incontinence severity and bladder diary duration.
Wein AJ; Khullar V; Wang JT; Guan Z
BJU Int; 2007 Feb; 99(2):360-3. PubMed ID: 17155987
[TBL] [Abstract][Full Text] [Related]
18. Prospective open label study of solifenacin for overactive bladder in children.
Bolduc S; Moore K; Nadeau G; Lebel S; Lamontagne P; Hamel M
J Urol; 2010 Oct; 184(4 Suppl):1668-73. PubMed ID: 20728124
[TBL] [Abstract][Full Text] [Related]
19. Solifenacin: as effective in mixed urinary incontinence as in urge urinary incontinence.
Kelleher C; Cardozo L; Kobashi K; Lucente V
Int Urogynecol J Pelvic Floor Dysfunct; 2006 Jun; 17(4):382-8. PubMed ID: 16283422
[TBL] [Abstract][Full Text] [Related]
20. Solifenacin for overactive bladder with incontinence: symptom bother and health-related quality of life outcomes.
Garely AD; Lucente V; Vapnek J; Smith N
Ann Pharmacother; 2007 Mar; 41(3):391-8. PubMed ID: 17341526
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
